ClinicalTrials.gg
CompletedNCT03620747Updated Mar 16, 2023Results posted

Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up)

A Phase 3 interventional study of Dupilumab SAR231893 (REGN668) in Asthma, sponsored by Sanofi. Completed at 132 sites in 10 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-03-16.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
393
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing dupilumab in Asthma — 7 open to participants now, 12 under way, 2 of them phase 3. dupilumab · Asthma.

Enrollment
7th of 31
393 · median 120
Started
2018
with 1 other
Phase 3
11 of 31
2 open now
Registered
10th of 31
by date
Lead sponsor
15 of 31
Sanofi

Among the 31 studies testing dupilumab in Asthma, this one is the 7th largest by enrollment, is one of 2 that started in 2018, is one of 11 in phase 3, and was the 10th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

7 of the 31 studies testing dupilumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing dupilumab in Asthma, or all of them as a file.
02

Study summary

Primary Objective:

To describe the long-term safety of dupilumab in treatment of participants with moderate to severe asthma who completed the previous asthma clinical trial (TRAVERSE-LTS12551).

Read the detailed description

Duration per participant was until dupilumab approval for use in asthma and market availability to the participant, or a maximum of 144 weeks (i.e., about 3 years) after the start of treatment (Visit 1), whichever came first.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with asthma who completed the treatment period in the previous dupilumab asthma clinical study LTS12551.
  • Signed written .

Exclusion criteria

Exclusion criteria:

  • Participants who experienced any systemic reactions to the medicinal product in the previous dupilumab asthma study LTS12551, which, in the opinion of the Investigator, could indicate that continued treatment with dupilumab might present an unreasonable risk for the participant.
  • comorbidity/lung disease other than asthma.
  • Participants with active disease or participants who, as per Investigator's medical judgment, were suspected of having high risk for developing autoimmune disease.
  • History of within 5 years before enrollment except completely treated in situ carcinoma of the cervix, completely treated and resolved non- squamous or basal cell carcinoma of the skin.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
393 participants (actual)

Study arms

  • Experimental
    Dupilumab

    Participants received subcutaneous (SC) dose of dupilumab 300 milligrams (mg) every 2 weeks (q2w) from Week 0 up to Week 132. Participants who discontinued treatment for greater than or equal to (\>=) 6 weeks after study LTS12551 (NCT02134028), received a 600 mg loading dose of dupilumab on Week 0. Participants were also on background dose of medium or high dose inhaled corticosteroid (ICS) as maintained in study LTS12551 in combination with controllers (and/or oral corticosteroid \[OCS\] for those participants from the original parent study EFC13691 \[NCT02528214\]). Salbutamol/albuterol hydrofluoroalkane pressurized metered dose inhalers (MDI) or levosalbutamol/levalbuterol hydrofluoroalkane pressurized MDI were given as reliever medication as needed during the study.

    Drug: Dupilumab SAR231893 (REGN668)

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had to have a causal relationship with the treatment. TEAEs were the AEs that developed or worsened or became serious during the TEAE period (defined as the time from the first dose of the investigational medicinal product \[IMP\] up to 12 weeks after the last dose of the IMP).

    Time frame: From first dose of IMP up to 12 weeks after last dose of IMP (maximum duration: up to 144 Weeks)

  2. Treatment-emergent Adverse Event Rate (Event Per 100 Participant-years)

    An AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had to have a causal relationship with the treatment. TEAEs were the AEs that developed or worsened or became serious during the TEAE period (defined as the time from the first dose of the IMP up to 12 weeks after last dose of the IMP). TEAE event rate was defined as the number of TEAE events per 100 participant-years.

    Time frame: From first dose of IMP up to 12 weeks after last dose of IMP (maximum duration: up to 144 Weeks)

Secondary outcomes

  1. Adverse Events of Special Interest (AESIs) Event Rate (Event Per100 Participant-years)

    An AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had to have a causal relationship with the treatment. AESIs were AE (serious or non-serious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the investigator to the Sponsor was required. AESI event rate was defined as the number of AESI events per 100 participant-years.

    Time frame: From first dose of IMP up to 12 weeks after last dose of IMP (maximum duration: up to 144 Weeks)

  2. Percentage of Participants With Treatment-emergent Serious Adverse Events (TESAEs), Adverse Events of Special Interest (AESIs) and AEs Leading to Study Discontinuation

    AE: any untoward medical occurrence in participants that received IMP and did not necessarily had to have causal relationship with treatment. TEAEs: AEs developed/worsened in grade/become serious during the TEAE period (from first dose of IMP up to 12 weeks after last dose of IMP).SAE: any untoward medical occurrence at any dose resulted in death, was life-threatening, required inpatient hospitalization, prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was congenital anomaly/birth defect or was medically important event. AESI: AE (serious/non-serious) of scientific and medical concern specific to Sponsor's product/program, for which ongoing monitoring and immediate notification by Investigator to Sponsor required.

    Time frame: From first dose of IMP up to 12 weeks after last dose of IMP (maximum duration: up to 144 Weeks)

07

Results

Posted Mar 16, 2023

Participant flow

The study was conducted at 138 sites in 10 countries. A total of 393 participants were enrolled in the study between 30 August 2018 and 27 August 2020.

Participant flow — Overall Study
MilestoneDupilumab
Started393
Completed374
Not completed19
Withdrew: Participant decision7
Withdrew: Adverse event6
Withdrew: Lack of efficacy1
Withdrew: Poor compliance to protocol2
Withdrew: Other-unspecified3

Outcome measures

PrimaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had to have a causal relationship with the treatment. TEAEs were the AEs that developed or worsened or became serious during the TEAE period (defined as the time from the first dose of the investigational medicinal product \[IMP\] up to 12 weeks after the last dose of the IMP).

Time frame:
From first dose of IMP up to 12 weeks after last dose of IMP (maximum duration: up to 144 Weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
percentage of participantsDupilumab
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)54.5 (47.40 to 62.26)
PrimaryTreatment-emergent Adverse Event Rate (Event Per 100 Participant-years)

An AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had to have a causal relationship with the treatment. TEAEs were the AEs that developed or worsened or became serious during the TEAE period (defined as the time from the first dose of the IMP up to 12 weeks after last dose of the IMP). TEAE event rate was defined as the number of TEAE events per 100 participant-years.

Time frame:
From first dose of IMP up to 12 weeks after last dose of IMP (maximum duration: up to 144 Weeks)
Reported as:
Number · events per 100 participant-years
Treatment-emergent Adverse Event Rate (Event Per 100 Participant-years)
events per 100 participant-yearsDupilumab
Treatment-emergent Adverse Event Rate (Event Per 100 Participant-years)171.4 (162.71 to 180.43)
SecondaryAdverse Events of Special Interest (AESIs) Event Rate (Event Per100 Participant-years)

An AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had to have a causal relationship with the treatment. AESIs were AE (serious or non-serious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the investigator to the Sponsor was required. AESI event rate was defined as the number of AESI events per 100 participant-years.

Time frame:
From first dose of IMP up to 12 weeks after last dose of IMP (maximum duration: up to 144 Weeks)
Reported as:
Number · events per 100 participant-years
Adverse Events of Special Interest (AESIs) Event Rate (Event Per100 Participant-years)
events per 100 participant-yearsDupilumab
Adverse Events of Special Interest (AESIs) Event Rate (Event Per100 Participant-years)6.0 (4.40 to 7.99)
SecondaryPercentage of Participants With Treatment-emergent Serious Adverse Events (TESAEs), Adverse Events of Special Interest (AESIs) and AEs Leading to Study Discontinuation

AE: any untoward medical occurrence in participants that received IMP and did not necessarily had to have causal relationship with treatment. TEAEs: AEs developed/worsened in grade/become serious during the TEAE period (from first dose of IMP up to 12 weeks after last dose of IMP).SAE: any untoward medical occurrence at any dose resulted in death, was life-threatening, required inpatient hospitalization, prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was congenital anomaly/birth defect or was medically important event. AESI: AE (serious/non-serious) of scientific and medical concern specific to Sponsor's product/program, for which ongoing monitoring and immediate notification by Investigator to Sponsor required.

Time frame:
From first dose of IMP up to 12 weeks after last dose of IMP (maximum duration: up to 144 Weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Serious Adverse Events (TESAEs), Adverse Events of Special Interest (AESIs) and AEs Leading to Study Discontinuation
percentage of participantsDupilumab
TESAEs5.6
AESIs6.1
AEs leading to study discontinuation1.5

Adverse events

Collected over From first dose of IMP up to 12 weeks after last dose of IMP (maximum duration: up to 144 Weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dupilumab5/393 (1.3%)22/393 (5.6%)93/393 (23.7%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventDupilumab
AsthmaRespiratory, thoracic and mediastinal disorders4/393
COVID-19Infections and infestations3/393
COVID-19 pneumoniaInfections and infestations3/393
Cardiac failure congestiveCardiac disorders1/393
Myocardial infarctionCardiac disorders1/393
EpilepsyNervous system disorders1/393
Pudendal canal syndromeNervous system disorders1/393
CataractEye disorders1/393
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/393
Respiratory failureRespiratory, thoracic and mediastinal disorders1/393
Most frequent other events
Most frequent other events
EventDupilumab
AsthmaRespiratory, thoracic and mediastinal disorders52/393
NasopharyngitisInfections and infestations33/393
COVID-19Infections and infestations22/393

Baseline characteristics

Analysis was performed on all enrolled participants.

Age, Continuous
Age, Continuous(years)Dupilumab
Mean52.1 ± 14.19
Sex: Female, Male
Sex: Female, Male(Participants)Dupilumab
Female231
Male162
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Dupilumab
08

Study locations

132 sites
  • Investigational Site Number :840099
    Gilbert, Arizona 85234, United States
  • Investigational Site Number :840087
    Scottsdale, Arizona 85248, United States
  • Investigational Site Number :840402
    Tucson, Arizona 85721, United States
  • Investigational Site Number :840132
    Little Rock, Arkansas 72209, United States
  • Investigational Site Number :840121
    San Jose, California 95117, United States
  • Investigational Site Number :840403
    Denver, Colorado 80206, United States
  • Investigational Site Number :840130
    Denver, Colorado 80246, United States
  • Investigational Site Number :840115
    Ocoee, Florida 34761, United States
  • Investigational Site Number :840055
    Sarasota, Florida 34239, United States
  • Investigational Site Number :840079
    Twin Falls, Idaho 83301, United States
  • Investigational Site Number :840032
    Fort Mitchell, Kentucky 41017, United States
  • Investigational Site Number :840064
    Bangor, Maine 04401, United States
  • Investigational Site Number :840052
    Chevy Chase, Maryland 20815, United States
  • Investigational Site Number :840073
    Gaithersburg, Maryland 20878, United States
  • Investigational Site Number :840018
    Minneapolis, Minnesota 55402, United States
  • Investigational Site Number :840102
    Saint Louis, Missouri 63141, United States
  • Investigational Site Number :840004
    Papillion, Nebraska 27103, United States
  • Investigational Site Number :840068
    West Long Branch, New Jersey 07764, United States
  • Investigational Site Number :840126
    Charlotte, North Carolina 28277, United States
  • Investigational Site Number :840907
    High Point, North Carolina 27262, United States
  • Investigational Site Number :840942
    Toledo, Ohio 43617, United States
  • Investigational Site Number :840067
    Philadelphia, Pennsylvania 19140, United States
  • Investigational Site Number :840091
    Pittsburgh, Pennsylvania 15241, United States
  • Investigational Site Number :840070
    Allen, Texas 75013, United States
  • Investigational Site Number :840062
    Amarillo, Texas 79109, United States
  • Investigational Site Number :840124
    Cypress, Texas 77429, United States
  • Investigational Site Number :840023
    Dallas, Texas 75231, United States
  • Investigational Site Number :840922
    Fort Worth, Texas 76109, United States
  • Investigational Site Number :840027
    Fort Worth, Texas 76244, United States
  • Investigational Site Number :840008
    San Antonio, Texas 78229, United States
  • Investigational Site Number :840035
    Draper, Utah 84020, United States
  • Investigational Site Number :840077
    Murray, Utah 84107, United States
  • Investigational Site Number :840057
    South Burlington, Vermont 05403, United States
  • Investigational Site Number :840059
    Fairfax, Virginia 22030, United States
  • Investigational Site Number :840951
    Bellingham, Washington 98225, United States
  • Investigational Site Number :032096
    Bahia Blanca, Buenos Aires B8000JRB, Argentina
  • Investigational Site Number :032091
    Capital Federal, Buenos Aires C1426ABP, Argentina
  • Investigational Site Number :032002
    La Plata, Buenos Aires B1900BNN, Argentina
  • Investigational Site Number :032006
    Rosario, Santa Fe S2000BRH, Argentina
  • Investigational Site Number :032005
    Rosario, Santa Fe S2000JKR, Argentina
  • Investigational Site Number :032004
    Buenos Aires, 2317, Argentina
  • Investigational Site Number :032003
    Ciudad Autonoma Bs As, C1121ABE, Argentina
  • Investigational Site Number :032097
    Ciudad Autonoma Buenos Aires, C1414AIF, Argentina
  • Investigational Site Number :032010
    Ciudad Autonoma Buenos Aires, C1414CGA, Argentina
  • Investigational Site Number :032001
    Ciudad Autonoma Buenos Aires, C1425BEN, Argentina
  • Investigational Site Number :032012
    San Miguel de Tucuman, T4000CHE, Argentina
  • Investigational Site Number :032009
    San Miguel De Tucumán, 4000, Argentina
  • Investigational Site Number :056003
    Gent, 9000, Belgium
  • Investigational Site Number :124006
    Vancouver, British Columbia V5Z 1M9, Canada
  • Investigational Site Number :124017
    Vancouver, British Columbia V6Z 1Y6, Canada
  • Investigational Site Number :124016
    Hamilton, Ontario L8N 4A6, Canada
  • Investigational Site Number :124013
    Ottawa, Ontario K1G 6C6, Canada
  • Investigational Site Number :124002
    Toronto, Ontario M5T 3A9, Canada
  • Investigational Site Number :124001
    Montreal, Quebec H2X 1P1, Canada
  • Investigational Site Number :124012
    Montreal, Quebec H3G 1A4, Canada
  • Investigational Site Number :124010
    Montréal, Quebec H4J 1C5, Canada
  • Investigational Site Number :124014
    Québec, Quebec G1V 4W2, Canada
  • Investigational Site Number :124007
    Trois-Rivieres, Quebec G8T 7A1, Canada
  • Investigational Site Number :124018
    Quebec, G1V 4G5, Canada
  • Investigational Site Number :250009
    Brest cedex 2, 29609, France
  • Investigational Site Number :250010
    Lille Cedex, 59037, France
  • Investigational Site Number :250006
    Lyon cedex 04, 69317, France
  • Investigational Site Number :250001
    Marseille, 13015, France
  • Investigational Site Number :250002
    Montpellier cedex 5, 34295, France
  • Investigational Site Number :250005
    Nantes cedex, 44093, France
  • Investigational Site Number :250008
    Strasbourg, 67091, France
  • Investigational Site Number :276006
    Berlin, 10787, Germany
  • Investigational Site Number :276010
    Frankfurt am Main, 60596, Germany
  • Investigational Site Number :276011
    Grosshansdorf, 22927, Germany
  • Investigational Site Number :276009
    Koblenz, 56068, Germany
  • Investigational Site Number :276005
    Ruedersdorf, 15562, Germany
  • Investigational Site Number :376001
    Kfar- Sava, 4428164, Israel
  • Investigational Site Number :376005
    Petach-Tikva, 4941492, Israel
  • Investigational Site Number :376002
    Rehovot, 76100, Israel
  • Investigational Site Number :392106
    Mizunami-shi, Gifu 509-6134, Japan
  • Investigational Site Number :392043
    Ota-shi, Gunma 373-0807, Japan
  • Investigational Site Number :392021
    Fukuyama-shi, Hiroshima 720-0001, Japan
  • Investigational Site Number :392108
    Hiroshima-shi, Hiroshima 734-8530, Japan
  • Investigational Site Number :392164
    Muroran-shi, Hokkaido 0143-0076, Japan
  • Investigational Site Number :392008
    Sapporo-shi, Hokkaido 062-8618, Japan
  • Investigational Site Number :392034
    Sapporo-shi, Hokkaido 064-0804, Japan
  • Investigational Site Number :392006
    Tomakomai-shi, Hokkaido 053-8506, Japan
  • Investigational Site Number :392162
    Kobe-shi, Hyogo 650-0017, Japan
  • Investigational Site Number :392020
    Naka-gun, Ibaraki 319-1113, Japan
  • Investigational Site Number :392011
    Sakaide-shi, Kagawa 762-8550, Japan
  • Investigational Site Number :392014
    Yokohama-shi, Kanagawa 231-8682, Japan
  • Investigational Site Number :392153
    Kyoto-shi, Kyoto 615-8087, Japan
  • Investigational Site Number :392170
    Osaki-shi, Miyagi 989-6183, Japan
  • Investigational Site Number :392045
    Uruma-shi, Okinawa 904-2293, Japan
  • Investigational Site Number :392119
    Kishiwada-shi, Osaka 596-8501, Japan
  • Investigational Site Number :392005
    Naruto-shi, Tokushima 772-0017, Japan
  • Investigational Site Number :392002
    Chuo-ku, Tokyo 103-0028, Japan
  • Investigational Site Number :392112
    Chuo-ku, Tokyo 104-0031, Japan
  • Investigational Site Number :392133
    Machida-shi, Tokyo 194-0023, Japan
  • Investigational Site Number :392177
    Ome-shi, Tokyo 198-0042, Japan
  • Investigational Site Number :392038
    Setagaya-ku, Tokyo 158-0097, Japan
  • Investigational Site Number :392167
    Shinagawa-ku, Tokyo 142-8666, Japan
  • Investigational Site Number :392173
    Tachikawa-shi, Tokyo 190-0012, Japan
  • Investigational Site Number :392185
    Akashi-shi, 674-0063, Japan
  • Investigational Site Number :392007
    Chuo-Ku, 103-0027, Japan

Showing the first 100 of 132 sites across 10 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2018 to primary completion in Feb 2022, 41 months.

Results were first posted in Mar 2023, 1 year after primary completion.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 41 months is above that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2018
First posted
Aug 8, 2018
StartActual
Aug 30, 2018
Primary completionActual
Feb 18, 2022
CompletionActual
Feb 18, 2022
Results first posted
Mar 16, 2023
Last update
Mar 16, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03620747
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Aug 8, 2018
Start date
Aug 30, 2018
Primary completion
Feb 18, 2022
Completion
Feb 18, 2022
Results posted
Mar 16, 2023
Last update
Mar 16, 2023

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion